The AMBAR Series
A four-part analysis of the landmark AMBAR trial — the largest and most rigorous study of plasma exchange for Alzheimer's disease. From the raw clinical data to the systemic barriers preventing adoption, this series covers everything physicians and families need to understand about the evidence.
4 Articles · by Allen P. Green, MD
In 2020, researchers published results from the AMBAR trial (Alzheimer Management By Albumin Replacement) — a multicenter, randomized, double-blind, placebo-controlled study across 41 sites in the United States and Spain. It remains the largest and most rigorous clinical trial ever conducted on therapeutic plasma exchange for Alzheimer's disease.
The results showed that plasma exchange with albumin replacement slowed cognitive and functional decline by 52–71% compared to placebo in patients with moderate Alzheimer's disease. Despite these findings, most neurologists remain unaware of the trial. This series examines the data, the independent validation, and the systemic factors behind the disconnect.
The Complete Analysis
The AMBAR trial didn't just show that plasma exchange slows Alzheimer's decline — it showed that the benefit occurs regardless of whether patients have high or low amyloid levels. This suggests the mechanism extends beyond amyloid removal to a broader restoration of the blood's protective environment.
Explore Your Options
If you or a loved one has been diagnosed with Alzheimer's disease, a discovery call with Dr. Green can help you understand whether therapeutic plasma exchange is appropriate for your situation. There is no obligation, and the conversation is complimentary.